Hermetica Superfood Encyclopedia
The Short Answer
Virola theiodora resin contains high concentrations of tryptamine alkaloids—primarily 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT)—which act as potent agonists at serotonin receptors (particularly 5-HT2A) to produce profound hallucinogenic and psychedelic effects. No controlled clinical trials have been conducted on V. theiodora specifically; the broader genus shows in vitro anti-inflammatory activity, with related species reducing nitric oxide production by 54–71% at 1–20 µg/mL in macrophage models, but these findings cannot be extrapolated to therapeutic use in humans.
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary KeywordVirola theiodora ebene
Ebene — botanical close-up
Health Benefits
**Serotonergic Psychoactivity (Ritual Context)**
Tryptamine alkaloids DMT and 5-MeO-DMT in the resin act as 5-HT2A receptor agonists, producing intense visionary states used in Yanomami shamanic healing ceremonies; no therapeutic clinical evidence exists for this application outside traditional contexts.
**In Vitro Anti-Inflammatory Activity (Related Species)**
Hydroethanolic extracts from related Virola elongata inhibit nitric oxide production by 54.8–71% at 1–20 µg/mL in LPS-stimulated RAW 264.7 macrophages, driven by phenolic compounds including ferulic acid and catechin; direct applicability to V. theiodora is unconfirmed.
**Cytokine Modulation (Preclinical)**
Extracts from Virola species reduce TNF-α by approximately 5–7% and IL-1β by 42–49% in macrophage cell models, suggesting upstream NF-κB pathway inhibition by stilbene and flavonoid constituents; no human data are available.
**Antiproliferative Effects (In Vitro)**
Stilbenes such as (Z)-3,5,4′-trimethoxystilbene from V. elongata inhibit Caco-2 colorectal cancer cell proliferation with an IC50 of approximately 0.25 µM, and polyketide fractions show selective cytotoxicity against ovarian and multidrug-resistant cell lines at IC50 2–4 µg/mL; clinical relevance is entirely unestablished.
**Alpha-Glucosidase Inhibition (Preclinical)**
Phenolic compounds, particularly ferulic acid and quercetin identified in related Virola species, inhibit α-glucosidase activity in enzymatic assays, suggesting potential relevance to postprandial glucose modulation; no in vivo or human studies confirm this effect for the genus.
**Gastroprotective Activity (Animal Model)**
Resin from Virola oleifera administered at 10–100 mg/kg orally reduced experimentally induced gastric ulcers by 59–97% in rodent models, with an LD50 exceeding 2500 mg/kg, indicating low acute oral toxicity in animals; no parallel data exist for V. theiodora.
**Analgesic/Anti-nociceptive Potential**
The neolignan compound oleiferin-C isolated from Virola species demonstrates analgesic potency approximately 7.5-fold greater than aspirin in preclinical assays; this compound class occurs across the Virola genus but has not been isolated or quantified specifically from V. theiodora resin.
Origin & History
Natural habitat
Virola theiodora is a medium-to-large canopy tree native to the western Amazon basin, distributed across Venezuela, Brazil, Colombia, and Peru, thriving in lowland tropical rainforest at elevations below 500 meters in humid, nutrient-poor oxisol soils. The tree belongs to the family Myristicaceae (nutmeg family) and produces a blood-red resinous exudate from its inner bark that is the primary source of bioactive tryptamine alkaloids. It is not cultivated commercially or agriculturally; all ethnobotanical use derives from wild-harvested specimens within indigenous Yanomami territories of the Amazon–Orinoco watershed.
“The preparation and use of ebene (also recorded as epená, yakee, paricá, and nyakwana) among Yanomami-speaking peoples of the Venezuelan and Brazilian Amazon represents one of the most extensively documented indigenous psychoactive practices in South America, first described scientifically by ethnobotanist Richard Evans Schultes in the mid-twentieth century following earlier colonial-era reports by missionaries and explorers dating to the eighteenth century. Ebene occupies a central role in Yanomami shamanism (xapiri practice), where trained shamans (hekura) inhale the snuff to enter trance states, communicate with spirit allies, diagnose illness, and conduct healing ceremonies for the community; its use is both restricted by social role and deeply integrated into cosmological belief systems. The ash admixture is not merely a diluent but serves a pharmacological function analogous to the role of monoamine oxidase inhibitors in ayahuasca, as alkaline pH from wood ash may slow mucosal degradation of tryptamines and enhance nasal absorption, though this has not been formally studied. Anthropological records by Jacques Lizot, Napoleon Chagnon, and Helena Valero, as well as Schultes and Hofmann's foundational text 'Plants of the Gods' (1979), provide the most substantive historical documentation of V. theiodora's ethnobotanical significance.”Traditional Medicine
Scientific Research
The evidence base for Virola theiodora specifically is extremely limited, consisting almost exclusively of ethnobotanical documentation of traditional Yanomami use and phytochemical identification of resin alkaloids; no controlled human clinical trials, randomized or observational, have been conducted on this species. Broader research on the Virola genus draws from in vitro cell culture experiments—notably RAW 264.7 macrophage assays for anti-inflammatory endpoints and cancer cell line panels for antiproliferative effects—which provide mechanistic hypotheses but cannot establish efficacy, safety, or dosing in humans. Animal pharmacology data, such as the V. oleifera gastroprotection study (10–100 mg/kg, rodent) and LD50 determinations (>2500 mg/kg), represent the highest tier of in vivo preclinical evidence available, and species-to-species extrapolation within the genus carries substantial uncertainty. The research quality is rated as preliminary; the genus warrants phytochemical characterization of V. theiodora specifically before any preclinical-to-clinical translation could be considered.
Preparation & Dosage
Traditional preparation
**Traditional Ebene Snuff (Yanomami Method)**
Inner bark is scraped to collect the red-orange resinous exudate, which is then slowly dried over low heat or open flame, ground into a fine dark powder, and mixed with alkaline ash from burned Cecropia leaves (or similar species) at approximately 1:1 to 3:1 resin-to-ash ratios; the insufflated dose used ritually is not quantified in the literature.
**Insufflation Route**
Powdered ebene is blown forcefully into the nasal passages of the recipient through a hollow bamboo or bone tube by another person; self-administration by tube is also practiced; onset of hallucinogenic effects occurs within minutes due to rapid nasal mucosal absorption of tryptamines.
**In Vitro Research Concentrations (Not Applicable to Humans)**
Anti-inflammatory effects in macrophage assays were observed at 1–20 µg/mL of hydroethanolic extract from related species; antiproliferative IC50 values ranged from 0.25 µM (stilbenes) to 2–4 µg/mL (polyketides) in cancer cell lines.
**Animal Research Doses (Not Applicable to Humans)**
10–100 mg/kg; no human equivalent dose (HED) calculation has been published for any Virola species preparation
Gastroprotection in rodents used resin doses of .
**No Standardized Commercial Supplement Form Exists**
V. theiodora is not available as a standardized extract, capsule, tincture, or nutraceutical product; no pharmacopeial monograph or standardization percentage has been established for any constituent.
Nutritional Profile
Virola theiodora resin is not a nutritional ingredient and contributes no meaningful macronutrients, micronutrients, vitamins, or minerals in the quantities used ethnobotanically. The bioactive phytochemical profile is dominated by indole tryptamine alkaloids—principally 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT)—present in the resin at concentrations sufficient to produce psychoactive effects via insufflation; precise quantification (% dry weight) has not been published for authenticated V. theiodora samples in peer-reviewed literature. Related Virola species contribute a secondary phytochemical profile including phenolic acids (ferulic acid, gallic acid), flavonoids (catechin, rutin, quercetin), neolignans (oleiferin-class compounds), stilbenes ((Z)-3,5,4′-trimethoxystilbene, resveratrol), and polyketides, with total phenolic content reported at approximately 14.6% dry weight in V. elongata bark extracts. Bioavailability data are absent for all phytochemical classes from V. theiodora; tryptamine alkaloids are known to be subject to rapid first-pass metabolism by monoamine oxidase A when ingested orally, explaining the traditional preference for insufflation as the route of administration.
How It Works
Mechanism of Action
The primary psychoactive mechanism of V. theiodora resin operates through its tryptamine alkaloids—5-MeO-DMT and DMT—which structurally mimic serotonin and act as high-affinity full or partial agonists at 5-HT2A, 5-HT2C, and 5-HT1A receptors in the central nervous system, triggering downstream Gq/11-protein signaling cascades and altered cortical excitability that underlie hallucinogenic perception. Beyond tryptamines, phenolic constituents including ferulic acid and catechin suppress the NF-κB transcription factor pathway, reducing pro-inflammatory gene expression and attenuating macrophage release of TNF-α, IL-1β, and inducible nitric oxide synthase (iNOS)-derived NO. Stilbene compounds such as (Z)-3,5,4′-trimethoxystilbene interfere with cell cycle progression in tumor cells, likely through disruption of tubulin polymerization and activation of apoptotic caspase pathways, analogous to the mechanism described for resveratrol and related stilbenoids. Alpha-glucosidase inhibition by polyphenols (ferulic acid, quercetin) proceeds through competitive or mixed-mode binding at the enzyme's active site, slowing disaccharide hydrolysis and carbohydrate absorption, though this mechanism is inferred from related species and chemical class data rather than direct study of V. theiodora.
Clinical Evidence
No clinical trials have been conducted on Virola theiodora or its isolated constituents in human subjects, and the ingredient does not appear in any registered clinical trial database as an investigational product. The available evidence is confined to in vitro pharmacology of related Virola species (V. elongata, V. oleifera, V. venosa), with outcomes including percentage reductions in inflammatory markers and IC50 values for antiproliferative effects measured in cell culture systems. These preclinical findings, while biologically plausible, have effect sizes and concentrations that cannot be directly translated to human therapeutic doses, and no pharmacokinetic or bioavailability data exist to bridge in vitro to in vivo relevance. Confidence in any health claim for V. theiodora as a therapeutic agent is therefore very low, and the ingredient's primary documented use—as a hallucinogenic ritual snuff—has not been evaluated under any controlled or ethical clinical research framework.
Safety & Interactions
Virola theiodora resin poses significant psychoactive risks at ritual doses due to high tryptamine content; acute effects include intense auditory and visual hallucinations, tachycardia, hypertension, nausea, and transient dissociation, with reported accounts of distressing psychological reactions and physical discomfort during the onset phase of ebene insufflation. Tryptamine alkaloids (DMT, 5-MeO-DMT) carry a theoretical risk of serotonin syndrome when combined with serotonergic drugs including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), lithium, and tramadol; this interaction has not been formally studied for V. theiodora but is inferred from the pharmacology of the alkaloid class. The ingredient is absolutely contraindicated in individuals with personal or family history of psychotic disorders, bipolar disorder type I, or severe cardiovascular disease; it is contraindicated during pregnancy and lactation due to unknown fetal safety and the physiological stress of the acute psychoactive response. No maximum safe dose has been established for any population; human safety data are entirely absent from the peer-reviewed literature, and the substance is legally controlled in numerous jurisdictions as a source of scheduled tryptamine alkaloids.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Virola theiodoraebeneepenáyakeenyakwanaparicáblood tree resin
Frequently Asked Questions
What is ebene snuff made from and how is it prepared?
Ebene is a hallucinogenic snuff prepared by the Yanomami people from the inner bark resin of Virola theiodora trees. The resin is scraped, dried over heat, ground into powder, and mixed with alkaline ash from burned Cecropia leaves at approximately 1:1 to 3:1 ratios; the resulting powder is then blown forcefully into the nasal passages through a bamboo tube, producing rapid onset of visionary effects due to mucosal absorption of tryptamine alkaloids DMT and 5-MeO-DMT.
What are the active compounds in Virola theiodora?
The primary psychoactive constituents of Virola theiodora resin are tryptamine alkaloids, principally N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), which act as serotonin 5-HT2A receptor agonists to produce hallucinogenic effects. Related Virola species also contain phenolic acids (ferulic acid, gallic acid), flavonoids (catechin, rutin), stilbenes, and neolignans with anti-inflammatory and antiproliferative properties in preclinical studies, though these have not been specifically quantified in V. theiodora.
Is Virola theiodora legal and is it safe to use?
Virola theiodora is a source of scheduled tryptamine alkaloids (DMT and 5-MeO-DMT), which are controlled substances in many countries including the United States, United Kingdom, and most of the European Union, making possession or preparation of the resin illegal in those jurisdictions. The safety profile in humans is entirely undocumented in clinical research; known risks include intense psychoactive reactions, cardiovascular stimulation, and potentially dangerous interactions with serotonergic medications including SSRIs, MAOIs, and SNRIs.
Has Virola theiodora been studied in clinical trials?
No clinical trials have been conducted on Virola theiodora in human subjects, and it does not appear in any registered clinical trial database as an investigational compound. The available scientific evidence is limited to ethnobotanical documentation, in vitro pharmacology studies on related Virola species (such as V. elongata and V. oleifera), and a small number of rodent studies; the evidence score for therapeutic use is accordingly very low (2 out of 10 on a preclinical evidence scale).
How does Virola theiodora differ from ayahuasca?
Both Virola theiodora-based ebene and ayahuasca contain DMT as a primary psychoactive alkaloid, but they differ fundamentally in route of administration, preparation, and cultural context: ebene is insufflated (snorted) as a dry powder, allowing tryptamines to bypass first-pass hepatic metabolism via nasal mucosal absorption, whereas ayahuasca is an oral brew that requires co-ingestion of MAO-A inhibitors (harmine, harmaline from Banisteriopsis caapi) to prevent gut degradation of DMT. Ebene is a Yanomami shamanic preparation, while ayahuasca originates from Quechua-speaking Amazonian traditions and involves a separate set of plant species and ceremonial contexts.
What are the safety concerns and contraindications for Virola theiodora use?
Virola theiodora contains psychoactive tryptamines (DMT and 5-MeO-DMT) that produce intense altered states and carry risks including psychological distress, elevated blood pressure, and potential triggering of underlying mental health conditions. It is contraindicated in individuals with cardiovascular disease, uncontrolled hypertension, schizophrenia spectrum disorders, or those taking serotonergic medications (SSRIs, MAOIs). The substance is illegal in most countries outside anthropological/traditional contexts, and no medical supervision framework exists for non-traditional use.
Does Virola theiodora interact with psychiatric or cardiovascular medications?
Yes, Virola theiodora's tryptamine alkaloids can interact dangerously with serotonergic drugs including SSRIs, SNRIs, and monoamine oxidase inhibitors (MAOIs), potentially triggering serotonin syndrome. Co-use with stimulants, antihypertensives, or other cardiovascular medications is contraindicated due to risk of hypertensive crisis and arrhythmias. Any consideration of use requires complete discontinuation of relevant medications under medical supervision, which is not feasible in most jurisdictions.
What is the difference between traditional Yanomami preparation methods and modern extraction forms of Virola theiodora?
Traditional Yanomami ebene snuff involves mechanical grinding of resin and bark into a fine powder inhaled nasally during ceremonial contexts with ritualistic and social containment. Modern extraction attempts (tinctures, concentrates) isolate alkaloids without the traditional ceremonial framework, increasing risks of unpredictable dosing and psychological harm. The traditional preparation's efficacy in Yanomami healing ceremonies cannot be separated from cultural, social, and environmental context, and extrapolating safety or benefit claims to isolated modern forms lacks scientific support.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w yanomami-ebene-plants-virola-theiodora curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
